U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C17H29N4O7.Gd
Molecular Weight 558.68
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GADOTERIDOL

SMILES

[Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1

InChI

InChIKey=DPNNNPAKRZOSMO-UHFFFAOYSA-K
InChI=1S/C17H32N4O7.Gd/c1-14(22)10-18-2-4-19(11-15(23)24)6-8-21(13-17(27)28)9-7-20(5-3-18)12-16(25)26;/h14,22H,2-13H2,1H3,(H,23,24)(H,25,26)(H,27,28);/q;+3/p-3

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB00597

Gadoteridol (INN) is a gadolinium-based MRI contrast agent, used particularly in the imaging of the central nervous system. It is sold under the brand name ProHance. Gadoteridol is a paramagnetic agent and, as such, develops a magnetic moment when placed in a magnetic field. The relatively large magnetic moment produced by the paramagnetic agent results in a relatively large local magnetic field, which can enhance the relaxation rates of water protons in the vicinity of the paramagnetic agent. In magnetic resonance imaging (MRI), visualization of normal and pathologic brain tissue depends in part on variations in the radiofrequency signal intensity that occur with 1) differences in proton density; 2) differences of the spin-lattice or longitudinal relaxation times (T1); and 3) differences in the spin-spin or transverse relaxation time (T2). When placed in a magnetic field, gadoteridol decreases T1 relaxation times in the target tissues. At recommended doses, the effect is observed with greatest sensitivity in the T1-weighted sequences. Gadoteridol does not cross the intact blood-brain barrier and, therefore, does not accumulate in normal brain or in lesions that have a normal blood-brain barrier, e.g., cysts, mature post-operative scars, etc. However, disruption of the blood-brain barrier or abnormal vascularity allows accumulation of gadoteridol in lesions such as neoplasms, abscesses, and subacute infarcts. The pharmacokinetics of ProHance in various lesions is not known.

CNS Activity

Curator's Comment: Gadoteridol does not cross the intact blood-brain barrier and, therefore, does not accumulate in normal brain or in lesions that have a normal blood-brain barrier, e.g., cysts, mature post-operative scars.

Originator

Curator's Comment: ProHance (gadoteridol, developed by Bristol-Myers Squibb, now marketed by Bracco Diagnostics) in 1991 and 1992 # Bristol-Myers Squibb

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
PROHANCE

Approved Use

Gadoteridol Injection is indicated for use in MRI in adults and children over 2 years of age to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues.

Launch Date

1993
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.57 h
0.3 mmol/kg single, intravenous
dose: 0.3 mmol/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GADOTERIDOL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.3 mmol/kg 1 times / day single, intravenous
Highest studied dose
Dose: 0.3 mmol/kg, 1 times / day
Route: intravenous
Route: single
Dose: 0.3 mmol/kg, 1 times / day
Sources:
unknown, 56.7 (6 - 93)
n = 6163
Health Status: unknown
Age Group: 56.7 (6 - 93)
Sex: M+F
Population Size: 6163
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
Patents

Sample Use Guides

ADULTS: The recommended dose of (Gadoteridol) Injection is 0.1 mmol/kg (0.2mL/kg) administered as a rapid intravenous infusion (10 mL/min-60 mL/min) or bolus ( >60 mL/min). CHILDREN (2-18 years): The recommended dose is 0.1 mmol/kg (0.2mL/kg) administered as a rapid intravenous infusion (10 mL/min-60 mL/min) or bolus (> 60 mL/min).
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Name Type Language
GADOTERIDOL
HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
NSC-760055
Code English
GADOTERIDOL [USP IMPURITY]
Common Name English
SQ 32,692
Code English
(±)-(10-(2-HYDROXYPROPYL)-1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIACETATO(3-))GADOLINIUM.
Common Name English
GADOTERIDOL [USP-RS]
Common Name English
GADOTERIDOL [HSDB]
Common Name English
Gadoteridol [WHO-DD]
Common Name English
gadoteridol [INN]
Common Name English
PROHANCE
Brand Name English
GADOLINIUM, (10-(2-HYDROXYPROPYL)-1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIACETATO(3-)-N1,N4,N7,N10,O1,O4,O7,O10)-
Systematic Name English
GADOTERIDOL [USAN]
Common Name English
SQ-32692
Code English
GADOTERIDOL [ORANGE BOOK]
Common Name English
GADOTERIDOL [MI]
Common Name English
GADOTERIDOL [MART.]
Common Name English
GADOTERIDOL [JAN]
Common Name English
GADOTERIDOL [VANDF]
Common Name English
GADOTERIDOL [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175862
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
NDF-RT N0000180184
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
WHO-ATC V08CA04
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
NCI_THESAURUS C62358
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
WHO-VATC QV08CA04
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
Code System Code Type Description
WIKIPEDIA
GADOTERIDOL
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
PRIMARY
DRUG CENTRAL
1268
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
PRIMARY
CAS
120066-54-8
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
PRIMARY
MESH
C062402
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
PRIMARY
INN
6655
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
PRIMARY
PUBCHEM
60714
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
PRIMARY
CHEBI
31643
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
PRIMARY
DRUG BANK
DB00597
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
PRIMARY
ChEMBL
CHEMBL1200593
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
PRIMARY
NSC
760055
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
PRIMARY
RXCUI
25483
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
PRIMARY RxNorm
USAN
BB-97
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
PRIMARY
SMS_ID
100000084509
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
PRIMARY
EVMPD
SUB07866MIG
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
PRIMARY
MERCK INDEX
m5628
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
PRIMARY Merck Index
LACTMED
Gadoteridol
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
PRIMARY
HSDB
7549
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
PRIMARY
EPA CompTox
DTXSID2048662
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
PRIMARY
RS_ITEM_NUM
1287631
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
PRIMARY
FDA UNII
0199MV609F
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
PRIMARY
DAILYMED
0199MV609F
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
PRIMARY
NCI_THESAURUS
C65796
Created by admin on Sat Dec 16 15:49:42 GMT 2023 , Edited by admin on Sat Dec 16 15:49:42 GMT 2023
PRIMARY